Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Technologies Stock Is Soaring Today

By George Budwell – May 9, 2019 at 2:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Heplisav-B's commercial launch is starting to ramp up.

What happened

Dynavax Technologies (DVAX -1.47%), a small-cap commercial-stage biotech, saw its shares gain as much as 18% in early action today. What's boosting the biotech's stock?

Dynavax's shares are responding positively to the company's first-quarter earnings report. The big-ticket item is that the company's hepatitis B vaccine, Heplisav-B, is finally gaining traction after a painfully slow start to its commercial launch. As proof, the vaccine's sales hit $5.6 million in the first quarter, representing a healthy 43% bump compared to the fourth quarter of 2018.

Drawing of a rocket launching from an open hand against a stormy background

Image source: Getty Images.

So what

Per its press release, Dynavax noted that Heplisav-B has achieved sales in three out of the top four national retail pharmacy chains, and that a whopping 1,454 individual customers have now purchased the vaccine since launch. Now, Heplisav-B still has a long way to go to achieve the company's peak sales estimate of approximately $500 million per year. But the trend is at least heading in the right direction.

Over the past year, after all, investors were starting to openly wonder if Dynavax would ever be able to get the vaccine's commercial launch to pick up steam. That key concern now seems to be fading in the wake of these strong first-quarter results.

Now what

In addition to Heplisav-B's improving commercial trajectory, Dynavax also announced that its immuno-oncology candidate SD-101 would be featured in three presentations at the American Society of Clinical Oncology's Annual Meeting in June. It's no secret that Dynavax is hoping to snag a big-pharma partner for SD-101. These abstracts are an encouraging sign that a licensing deal is still a possibility.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$10.09 (-1.47%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.